Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapybenzinga_article·29 minutes agoAKTX+1.60%
The Value Chain Shift: From Software Consolidation to Industrial RepositioningGlobal Report·5 hours agoVMEO0.00%SM+0.31%
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy | AKTX Stock NewsStockTitan·11 hours agoAKTX+1.60%
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload PlatformUnusual Whales·Aug 13 at 03:16 PMAKTX+1.60%
Akari net loss widens to $4.81 million in Q2 FY26; operating loss rises to $4.6 millionPUBT·Aug 13 at 03:04 PMAKTX+1.60%WXXWY+3.65%
The Great Unbundling of 2026: From Legacy Aggregators to Frontier InfrastructureGlobal Report·Aug 4 at 04:17 AMNSRGF+4.28%IRDM-1.32%
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation | AKTX Stock NewsStockTitan·Aug 3 at 11:50 PMAKTX+1.60%WHWK+1.94%
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology OpportunityGlobeNewswire·Jul 22 at 07:40 AMAKTX+1.60%WHWK+1.94%
